Exchange: NASDAQ·Updated 08:53 AM EDT
AZN logo

AZNAstraZeneca PLC

$188.58
$4.72
(2.57%)
Pre-Market
Prev Close $183.86
Reported EarningsApr 29
Mkt Cap$285.14B
Vol12,088.00
News
all
press releases
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO for NSCLC
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO for NSCLC Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical...
PR Newswire
News Placeholder
More News
News Placeholder
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
Astrazeneca (AZN) closed at $183.86 in the latest trading session, marking a -3.04% move from the prior day.
Zacks
News Placeholder
AZN vs. ILMN: Which Stock Should Value Investors Buy Now?
AZN vs. ILMN: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
J&J's Innovative Medicine Business in Q2: Here's What to Watch
JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.
Zacks
News Placeholder
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
Zacks
News Placeholder
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe
AstraZeneca reported positive HPP trial data while Enhertu gained EU approval for HER2-positive solid tumors.read more...
Benzinga
News Placeholder
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe
AstraZeneca reported positive HPP trial data while Enhertu gained EU approval for HER2-positive solid tumors.read more...
Benzinga
News Placeholder
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
Zacks
News Placeholder
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Astrazeneca (AZN) closed at $185.68, indicating a +1.45% shift from the previous trading day.
Zacks
<
1
2
...
>

Advertisement|Remove ads.